Nursing Drug Cards
-
Upload
jenna-rasmussen -
Category
Documents
-
view
230 -
download
0
Transcript of Nursing Drug Cards
-
7/24/2019 Nursing Drug Cards
1/32
Trade Name:Cipro
Classifcation:Broad-Spectrum Antiinfectives
Use(s):Infections caused by susceptible organisms E
Proteus, staph.
Action:Interferes ith conversion of !"A fragments in
higher molecular eight ones. !"A gyrase inhibitors.
Contraindications:#ypersensitivity to $uinolones
Side Eects:#eadache, di%%iness, restlessness, "&'&!
Nursing implications: Assess for C"S symptoms, I()ratio, allergic reactions.
-
7/24/2019 Nursing Drug Cards
2/32
*E++)S S*AE
CLASSIFICATIN:Antianemic, iron
ACTIN:"ormal daily inta/e males 01-12 mg3 females 4-05 m
only 026 absorbed3 Iron absorbed by from duodenum and upp
7e7unum by active mechanism thru mucosal cells, combines it
transferring3 iron stored as hemosiderin or aggregated ferritin c
of liver, spleen, bone marro3 1&8 of iron in circulating +BC9s
IN!ICATINS:Prophyla:is, treatment of iron de;ciency and irde;ciency anemia9s3 dietary supplement for iron
USUAL !SA"E:Adults 822 mg&day
A!#E$SE $EACTINS< Constipation, gastric irritation, nausea
abdominal cramps, anore:ia, diarrhea, dar/-colored stools
NU$SIN" CNSI!E$ATINS< Substitution of one iron salt foranother ithout proper ad7ustment may result in serious over o
-
7/24/2019 Nursing Drug Cards
3/32
under dosing3 Eggs, mil/, co=ee or tea may signi;cantly inhibit
absorption.
A>)?ICII"
CLASSIFICATIN< Antibiotic, penicillin
ACTIN:Synthetic broad-spectrum penicillin closely related to
ampicillin3 Binds to bacterial cell all @PBP-0 and PBP-83 penicil
binding sites, causing cell death by inhibiting cell all synthes
bactericidal action3 spectrum is larger than penicillin9sIN!ICATINS:Ear, nose, and throat infections.
USUAL !SA"E:
)ver 2 /g< 522 mg $4hr or 522 mg $01hr3 under 2 /gI")P#E"
CASSI*ICAI)"< non-narcotic analgesic
-
7/24/2019 Nursing Drug Cards
5/32
ACI)"< !ecreases fever by 0 a hypothalamic e=ect leading to sand vasodilation and 1 inhibits the e=ect of pyrogens on thehypothalamic heat-regulating centers. >ay cause analgesia by inC"S prostaglandin synthesis3 hoever, due to minimal e=ects on
peripheral prostaglandin synthesis, acetaminophen has no anti-inammatory or uricosuric e=ects. !oes not cause any anticoague=ect or ulceration of the DI tract. Antipyretic and analgesic e=eccomparable to those of aspirin.I"!ICAI)"S< 0 Control of pain 1 +educes fever in bacterial or vinfections
SA !)SADE< Adults< 815-52 mg $hrA!'E+SE +EACI)"S< *e hen ta/en in usual therapeutic dose
upset in some3 Chronic and even acute to:icity can develop after
symptom-free usage
I"E+ACI)"S< Chronic Et)# F to:icity of larger therapeutic dos
barbiturates, carbama%epine, hydantoins, isonia%id, rifampin (
sul;npyra%one< F hepatoto:icity potential related to F liver brea
-
7/24/2019 Nursing Drug Cards
6/32
%G!+)C#)+)#IAHI!E
CLASSIFICATIN< Antihypertensive, combination drug
ACTIN< acts directly on the distal tubule to promote the e:cretiof sodium, bicarbonate, chloride, and uid3 Increases urinary p#3
#ydrochlorothia%ide promotes e:cretion of sodium and chloride a
ater by distal renal tubule3 Also increases e:cretion of potassium
smaller amounts of bicarbonate3 Antihypertensive e=ects due to
dilation of arterioles as ell as uid volume lossIN!ICATINS< #ypertension or edema in clients ho manifest
hypo/alemia on hydrochlorothia%ide alone3 in clients re$uiring a
and in hom hypo/alemia cannot be ris/ed3 usually not ;rst line
therapy e:cept hen avoiding hypo/alemia
A!#E$SE $EACTINS< "ausea ( vomiting, headache, anore:iaupset, diarrhea, atulence, di%%iness, photosensitivity
-
7/24/2019 Nursing Drug Cards
7/32
NU$SIN" CNSI!E$ATINS< Assess for alcoholism, monitor vi
signs and tests @reduce dose ith dysfunction3 drug is ta/en to lo
and reduce selling of e:tremities @ta/e in A> ith food to reduc
upset. rash, fever
A>)SI" #G!+)C#)+I!E
CLASSIFICATIN< Alpha-adrenergic bloc/ing drug
ACTIN< Bloc/ade of alpha0-receptors @probably alpha0a in the
prostateresults in rela:ation of smooth muscles in the bladder, ne
prostate3thus, urine o rate is improved and there is a decrease
symptoms of BP#IN!ICATINS< Signs and symptoms of BP#3 rule-out prostatic ca
before using tamsulosin
A!#E$SE$EACTINS< #eadache, di%%iness, pharyngitis&rhinitis
shoulder&nec/&bac/&e:tremity pain, asthenia, diarrhea, chest pain
NU$SIN"CNSI!E$ATINS< identify drugs prescribed to ensuof the drugs interact, especially cimetidine or Coumadin3 monitor
-
7/24/2019 Nursing Drug Cards
8/32
I(), 'S, eight, urodynamic studies3 note PSA levels, results of
digital rectal e:am3 ta/e as directed, do not che, crush, or open
Atenolol @enorminCLASSIFICATIN< Beta-Bloc/er
ACTIN< In therapeutic doses, atenolol selectively bloc/s beta0-
adrenergic receptors located chiey in cardiac muscle.
IN!ICATINS used to treat high blood pressure. It is also used t
angina and chest pain.A!#E$SE $EACTINS< Constipation, indigestion, dry mouth, di%
NU$SIN" CNSI!E$ATINS: Chec/ apical pulse before giving
drug, especially in patients receiving digitalis @both drugs slo A'
conduction. If belo 2 bpm @or other ordered parameter, ithh
and consult physician. >onitor apical pulse, BP, respirations, and
-
7/24/2019 Nursing Drug Cards
9/32
peripheral circulation throughout dosage ad7ustment period. Con
physician for acceptable parameters.
E"AAP+I >AEAE @'asotec
CLASSIFICATIN< CA+!I)'ASCA+ ADE"3 A"DI)E"SI"-C)"
E"HG>E @ACE I"#IBI)+3 A"I#GPE+E"SI'E
ACTIN< Angiotensin-converting en%yme @ACE inhibitor. ACE catthe conversion of angiotensin I to angiotensin II, a vasoconstricto
substance. herefore, inhibition of ACE decreases angiotensin II l
hich decreases vasopressor activity and aldosterone secretion.
IN!ICATINS >anagement of mild to moderate hypertension.
A!#E$SE $EACTINS
-
7/24/2019 Nursing Drug Cards
10/32
NU$SIN" CNSI!E$ATINS: >onitor BP for ;rst several days
therapy. If antihypertensive e=ect is diminished before 1 h, the
dose may be given as 1 divided doses. +eport transient hypotens
lightheadedness. )lder adults are particularly sensitive to drug-in
hypotension. Supervise ambulation until BP has stabili%ed.ab tests< >onitor serum potassium and be alert to symptoms of
hyper/alemia @J K5.L mE$&.
PA")P+AH)E
CLASSIFICATIN< DAS+)I"ESI"A ADE"3 P+))" P>P I"ACTINDastric acid pump inhibitor3 belongs to a class of antisecompounds. Dastric acid secretion is decreased by inhibiting the
APase en%yme system responsible for acid production.
IN!ICATINS Short-term treatment of erosive esophagitis assoc
ith gastroesophageal reu: disease @DE+!.A!#E$SE $EACTINS< !iarrhea, atulence, abdominal pain.
-
7/24/2019 Nursing Drug Cards
11/32
NU$SIN" CNSI!E$ATINS: >onitor for and immediately repo
angioedema or a severe s/in reaction. ab tests< rea breath test
after completion of therapy.
!IC)*E"AC S)!I>
CLASSIFICATIN< CE"+A "E+')S SGSE> ADE"3 A"ADES
A"IPG+EIC3 "SAI!ACTIN< Although its e:act mechanism of action has not been fu
elucidated, it appears to be a potent inhibitor of cycloo:ygenase,
decreasing the synthesis of prostaglandins.
IN!ICATINS Analgesic and antipyretic e=ects in symptomatic t
of rheumatoid arthritis, osteoarthritis, and an/ylosing spondylitis
acute gout.
-
7/24/2019 Nursing Drug Cards
12/32
A!#E$SE $EACTINSonitor BP for hypertension and b
sugar for hyperglycemia.
-
7/24/2019 Nursing Drug Cards
13/32
0. Acute pain related to< inammation and infection of the urethr
bladder and other urinary tract structures.
1. #yperthermia related to< inammatory reaction
8. Impaired rinary Elimination related to< fre$uent urination, urg
hesitancy
. +is/ for *luid 'olume !e;citrelated to< e:cessive evaporation
vomiting
5. !isturbed Sleep Pattern related to< pain and nocturia.
. noledge !e;cit< about condition, prognosis, and treatment
related toonitor input and output characteristics of the urine.+ational< provides information about renal function and presence of complications
1 !etermine the patientNs voiding patterns
8 Encourage increased uid inta/e+ationale< increased hydration ill ush the bacteria.
+evie the full bladder complaints+ational< urinary retention may occur causing tissue distension @bladder & /idney
5 )bservations of changes in mental status
-
7/24/2019 Nursing Drug Cards
15/32
L Collaborationonitor laboratory tests< electrolytes, creatinine+ational< control of renal dysfunction
#EPA+I"
CLASSIFICATIN< #eparin, Anticoagulant
ACTIN< !oes not dissolve previously formed clots, but forestalls enlargement and preve
from forming3 Potentiates inhibitory action of antithrombin III3 )ccurs due to formation of a
ith antithrombin III and causing a conformational change in antithrombin III molecule3 Ac
thrombin in coagulation is inhibited3 Also prevents formation of a stable ;brin clot by inhib
activation of ;brin-stabili%ing factor by thrombin
IN!ICATINS< Pulmonary&peripheral arterial embolism3 Prophyla:is and treatment of ven
thrombosis and e:tensions3 Atrial ;brillation ith emboli%ation3 reatment and diagnosis o
doses to prevent !' and PE in pregnant clients ith thromboembolism history and other
Prophyla:is of clotting in blood transfusions and others
A!#E$SE $EACTINS< #emorrhage ranging from minor local ecchymoses to ma7or hem
complications from any organ, chills, fever, urticaria, local irritation, erythema, mild pain,
INTE$ACTINS3 administer by deep sub in7ection t
local irritation, hematoma, and tissue sloughing and to prolong drug action3 utili%e H-trac/
QBunch techni$ue9 method3 do not administer ithin 1in of umbilicus @decreased vasculari
massage site, slight discoloration does not a=ect potency3 perform test dose @0,222 units
clients ith allergies or asthma history
"ENE$IC NA&E< >E)P+)) A++AE
CLASSIFICATIN< Beta-adrenergic Bloc/ing Agent
ACTIN< Combines reversibly mainly ith beta-adrenergic receptors to bloc/ the respons
sympathetic nerve impulses, circulating catecholamines, or adrenergic drugs3 Bloc/age of
receptors decreases heart rate, myocardial contractility, and cardiac output and slos A'
all of hich decreases blood pressure
-
7/24/2019 Nursing Drug Cards
17/32
IN!ICATINS< #ypertension3 Acute >I in hemodynamically stable patients3 Angina pecto
A!#E$SE $EACTINS< *atigue, di%%iness, depression, shortness of breath, bradycardia,
CNT$AIN!ICATINS< >I in clients ith a heart rate of less than 5 bpm, in second- or
heartbloc/, or if SBP is less than 022 mm #g3 moderate to severe cardiac failure
NU$SIN" CNSI!E$ATINS< !o not confuse metoprolol ith metoclopramide, metapro
misoprostol3 if transcient orsening of heart failure occurs, treat ith increased doses of d
need to loer dose of metoprolol or temporarily discontinue3 for C#*, do not increase dos
symptoms of orsening C#* have been stabili%ed3 if C#* clients e:perience symptomatic
reduce dose3 ta/e dose each day at same time3 do not stop suddenly
'itamin !
IN!ICATINS< management of hypocalcemia and resultant metabolic bone disease in pa
undergoing chronic renal dialysis3 indicated in management of secondary hyperparathyro
resultant metabolic bone disease in patients ith mild&moderate&severe chronic renal failu
dialysis3 management of hypocalcemia and clinical manifestations in patients ith postsu
hypoparathyroidism, idiopathichypoparathyroidism, and pseudohypoparathyroidism
-
7/24/2019 Nursing Drug Cards
18/32
A!#E$SE$EACTINS< #ypercalcemia syndrome or calcium into:ication3 ea/ness, hea
somnolence, "(', dry mouth, constipation, muscle pain, bone pain, metallic taste, anore:
pain, abdominal pain3 polyuria, polydipsia, nocturia, calci;c con7unctivitis, pancreatitis, ph
rhinorrhea, pruritis, hyperthermia, decreased libido, elevated B", albuminuria, hypercho
elevated SD) @AS and SDP @A and >A"G >)+E
CNT$AIN!ICATINS< Should not be ta/en to patients ith hypercalcemia or evidence
to:icity3 use in patients ith /non hypersensitivity to +ocaltrol @or drugs of same class o
inactive ingredients is contraindicated
NU$SIN"CNSI!E$ATINS< E=ectiveness is predicated on the assumption that each p
receiving an ade$uate daily inta/e of calcium3 advise patients to have dietary inta/e mini
mg daily3 patients should be advised of compliance ith dosage instructions and adheren
instructions about diet and calcium supplementation3 advise avoidance of the use of unap
nonprescription drugs3 carefully inform about S(S of hypercalcemia
"ENE$IC NA&E< ASPI+I" @ACEGSAICGCIC ACI!, ASA
CLASSIFICATIN< "onsteroidal, anti-inammatory drug, analgesic, antipyretic
ACTIN< E:hibits antipyretic, anti-inammatory, and analgesic e=ects3 Antipyretic due to
the hypothalamus, resulting in heat loss by vasodilation of peripheral blood vessels and p
-
7/24/2019 Nursing Drug Cards
19/32
seating3 Anti-inammatory mediated through inhibition of cyclo-o:ygenase, hich result
decrease in prostaglandin synthesis and other mediators of pain response
IN!ICATINS< Analgesic M Pain from integumentary structures, myalgias, neuralgias,arth
headache, dysmenorrheal, and similar types of pain3 gout3 Antipyretic, Anti-inammatory
osteoarthritis, SE, acute rheumatic fever, gout, and many other conditions
A!#E$SE $EACTINS< !yspepsia, nausea, epigastric, discomfort
CNT$AIN!ICATINS< #ypersensitivity to salicylates3 clients ith asthma, hay fever, or
have higher incidence of hypersensitivity3 severe anemia, history of blood coagulation def
con7unction ith anticoagulant therapy3 vitamin de;ciency
NU$SIN" CNSI!E$ATINS
< Enteric-coated or bu=ered tablets better tolerated by some3 ta/e ith full glass of ater3
epinephrine to counteract hypersensitivity3 ta/e temperature 0 hour after administering3 n
asthma, hay fever, ulcer disease or nasal polyps3 ta/e as directed3 administer ith meals
ater
"ENE$IC NA&E< >E*)+>I" #G!+)C#)+I!E
CLASSIFICATIN< )ral Antidiabetic, Biguanide
-
7/24/2019 Nursing Drug Cards
20/32
ACTIN< !ecreases hepatic glucose production, decreases intestinal absorption of glucos
peripheral upta/e and utili%ation of glucose3 does not cause hypoglycemia in either diabet
diabetic clients, and does not cause hyperinsulinemia3 insulin secretion remains unchange
fasting insulin levels and day-long plasma insulin response may decrease
IN!ICATINS< As monotherapy, as ad7unct to diet and e:ercise, to improve glycemic con
ith type 1 diabetes3 Immediate-release tablets and P) solution can be used in clients 02
older3 E:tended +elease form used to treat type 1 diabetes as initial therapy or in con7unc
sulfonylurea or insulin in clients 0L y&o and older
A!#E$SE $EACTINS< actic acidosis, hypoglycemia, diarrhea, nausea ( vomiting, asth
atulence, headache, abdominal pain&discomfort
NU$SIN" CNSI!E$ATINS< actic acidosis is a rare, but serious, metabolic complicati
occur due to metformin accumulation @52 6 fatal3 do not confuse Dlucophage ith Dluco
individuali%e dosage based on tolerance and e=ectiveness3 give ith meals and start at a
ith gradual escalation @ill reduce DI side e=ects3 may safely sitch
from metformin to metformin e:tended-release3 may cause a metallic taste @ill subside
"ENE$IC NA&E< Candesartan
-
7/24/2019 Nursing Drug Cards
21/32
CLASSIFICATIN< A+B
ACTIN< Angiotensin II receptor @type A0 antagonist. Angiotensin II is a potent vasocons
primary vasoactive hormone of the reninMangiotensinMaldosterone system. Candesartan s
bloc/s binding of angiotensin II to the A0 receptors found in many tissues @e.g., vascular
muscle, adrenal glands.
IN!ICATINSreating high blood pressure alone or ith other medicines. It is used in cepatients to treat heart failure. It may also be used for other conditions as determined by y
Candesartan is an angiotensin II receptor bloc/er @A+B. It or/s by rela:ing blood vessels
to loer blood pressure.
A!#E$SE $EACTINS< upper respiratory tract infection, di%%iness, bac/ pain, pharyngiti
NU$SIN" CNSI!E$ATINS< >onitor BP as therapeutic e=ectiveness is indicated by de
systolic and diastolic BP ithin 1 / ith ma:imal e=ect at M /. >onitor for transient h
in volume&salt-depleted patients3 if hypotension occurs, place in supine position and notify
>onitor BP periodically3 trough readings, 7ust prior to the ne:t scheduled dose, should be
possible. ab tests< Periodically monitor B" and creatinine, serum potassium, liver en%ym
ith di=erential.
-
7/24/2019 Nursing Drug Cards
22/32
"ENE$IC NA&E< Candesartan
CLASSIFICATIN< A+B
ACTIN< Angiotensin II receptor @type A0 antagonist. Angiotensin II is a potent vasocons
primary vasoactive hormone of the reninMangiotensinMaldosterone system. Candesartan sbloc/s binding of angiotensin II to the A0 receptors found in many tissues @e.g., vascular
muscle, adrenal glands.
IN!ICATINSreating high blood pressure alone or ith other medicines. It is used in cepatients to treat heart failure. It may also be used for other conditions as determined by y
Candesartan is an angiotensin II receptor bloc/er @A+B. It or/s by rela:ing blood vessels
to loer blood pressure.
A!#E$SE $EACTINS< upper respiratory tract infection, di%%iness, bac/ pain, pharyngiti
NU$SIN" CNSI!E$ATINS< >onitor BP as therapeutic e=ectiveness is indicated by de
systolic and diastolic BP ithin 1 / ith ma:imal e=ect at M /. >onitor for transient h
in volume&salt-depleted patients3 if hypotension occurs, place in supine position and notify
>onitor BP periodically3 trough readings, 7ust prior to the ne:t scheduled dose, should be
-
7/24/2019 Nursing Drug Cards
23/32
-
7/24/2019 Nursing Drug Cards
24/32
-
7/24/2019 Nursing Drug Cards
25/32
food to decrease DI upset3 do not share drugs3 /eep in safe place3 drug may cause di%%ine
drosiness3 may cause constipation, nausea( vomiting, rash&itching, and physical depend
alcohol and any other C"S depressants ithout provider approval3 tolerance may occur
)"!A"SE+)" #G!+)C#)+I!E
CASSI*ICAI)"< Antiemetic
ACI)"< Cytoto:ic chemotherapy is thought to release serotonin from enterochromaRn ce
small intestine3 the released serotonin may stimulate the vagal a=erent nerves through th
receptors, thus stimulating the vomiting ree:3 )ndansetron, a 5-#8 antagonist, bloc/s t
serotonin3 hether the drug acts centrally and&or peripherally to antagoni%e the e=ect of s
not /non
I"!ICAI)"S< Prevent "(' resulting from initial and repeated courses of cancer chemothe
including cisplatin, greater than 52 mg&m13 prevent "(' associated ith initial and repea
moderately emetogenic cancer chemotherapy3 Prevent "(' associated ith radiotherapy
receiving either total body irradiation, single high-dose fraction to the abdomen, or daily f
the abdomen
A!'E+SE +EACI)"S< !iarrhea, headache, di%%iness, malaise&fatigue, constipation, brady
hypotension, drosiness& sedation, an:iety&agitation, gynecological disorder, urinary reten
hypo:ia, pruritus, pyre:ia, shivers
-
7/24/2019 Nursing Drug Cards
26/32
"+SI"D C)"SI!E+AI)"S< !o not confuse Hofran ith Holoft, Hantac, or Hosyn3 do not e
P) or 4 mg I' daily ith impaired hepatic function3 1 mg&m )ndansetron in7ection re$uir
for administration for postop "('3 inspect visually for particulate matter and discoloration
administering3 drug is to prevent "('3 to be given e:actly as prescribed3 may cause dro
di%%iness3 do not perform activities that re$uire mental alertness until drug e=ects reali%ed
rash, diarrhea, constipation, altered respirations @brochospasms, or loss of response
ALEN!$NATE
CLASSIFICATIN< BISP#)SP#)"AE3 +EDA)+, B)"E >EAB)IS>
ACTIN< Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorpti
Antiresorption mechanism is not fully understood. It does, hoever, locali%e preferentiallysites of active bone turnover and has minimal to no interference ith bone minerali%ation
IN!ICATINS< Prevention and treatment of osteoporosis in postmenopausal omen, Pag
reatment of glucocorticoid-induced osteoporosis.
A!#E$SE $EACTINSEndocrine:#ypocalcemia, hypophosphatemia. "I:Esophageal i
and ulceration, nausea, vomiting, abdominal pain, dyspepsia,diarrhea, constipation,
atulence. t'er: Arthralgias, myalgias, headache, rash.
INTE$ACTINS
!rug:$anitidineincreases alendronate availability. Food:Calciuman@especially dairy products reduce alendronate absorption.
-
7/24/2019 Nursing Drug Cards
27/32
CNT$AIN!ICATINS< #ypersensitivity to alendronate or other bisphosphonates3 severe
impairment @Clcr85 m&min3 hypocalcemia3 abnormalities3 lactation, pregnancy @category
NU$SIN" CNSI!E$ATINSonitor albumin-ad7usted serum calcium, serum phosphate, serum al/aline pho
fasting and 1 h urinary calcium, and serum electrolytes. Periodically monitor renal and liv
!iagnostic test< Bone density scan every 01M04 mo.
!iscontinue drug if the Clcr85 m&min.
"ENE$IC NA&E< CACI> CA+B)"AE
CLASSIFICATIN< Calcium salt
ACTIN< Calcium is essential for maintaining normal function of nerves, muscles, the s/eand permeability of cell membranes and capillaries3 normal serum calcium level is T-02. 5.1 mE$&. #ypocalcemia is characteri%ed by muscular ;brillation, titching, s/eletal musleg cramps, titanic spasms, cardiac arrythmias, smooth muscle hypere:citability, mental dand an:iety states
IN!ICATINS< >ild hypocalcemia3 Antacid @including heartburn, sour stomach, and acid ianithyperphosphatemic
USUAL !SA"E< #ypocalcemia&"utritional supplement M 0.15-0.5 grams 0-8 times daily ithout meals3 antihyperphosphatemic M 5-08 grams daily in divided doses ith meals
-
7/24/2019 Nursing Drug Cards
28/32
A!#E$SE $EACTINS< After P) use M DI irritation, constipation, headache, mild hyperca@anore:ia, "('
CNT$AIN!ICATINS< !igitali%ed clients, sarcoidosis, renal or cardiac disease, ventricu;brillation, cancer clients ith bone metastases3 renal calculi, hypophosphatemia3 hyperc
NU$SIN" CNSI!E$ATINS< Perform thorough nursing history, noting clinical presenta
indications for therapy, and any precipitating causes3 list drugs prescribed, especially if redigitalis products @may be contraindicated3 monitor calcium levels and renal function3 assor parathyroid disease3 note bone density ;ndings3 supplements need vitamin ! to facilitaabsorption3 report adverse side e=ects, lac/ of desired response, and /eep all follo-up apto evaluate drug response
CLT$I&ALE
CLASSIFICATIN< A"II"*ECI'E3 A"IBI)IC3 A"I*"DA
ACTIN< #as broad-spectrum fungicidal activity. Acts by altering fungal cell membrane pe
permitting loss of phosphorous compounds, potassium, and other essential intracellular co
ith conse$uent loss of ability to replicate.
IN!ICATINS< !ermal infections including tinea pedis, tinea cruris, tinea corporis, tinea v
also vulvovaginal and oropharyngeal candidiasis.
S C S D b l li f i i l d i i
-
7/24/2019 Nursing Drug Cards
29/32
A!#E$SE $EACTINSDI< Abnormal liver function tests3 occasional nausea and vomiting
troche. S/in< Stinging, erythema, edema, vesication, des$uamation, pruritus, urticaria, s/
;ssures. rogenital< >ild burning sensation, loer abdominal cramps, bloating, cystitis, ur
urinary fre$uency, vulval erythema and itching, pain and vaginal soreness during intercou
INTE$ACTINS!rug: Intraaginal preparations ma* inactiate S+E$&ICI!ES,
CNT$AIN!ICATINS< )phthalmic uses3 systemic mycoses. Safe use during pregnancy
for oral troches, category B for topical preparations, lactation, and in children 8 y not es
NU$SIN" CNSI!E$ATINS-SPA+I"D !I+EICS, A"DI)E"SI"-C)"'E+I"DE"HG>E @ACE I"#IBI)+S may cause hyper/alemia.CNT$AIN!ICATINS< Severe renal impairment3 severe hemolytic reactions3 untreated disease3 crush syndrome3 early postoperative oliguria @e:cept during DI drainage3 adynamacute dehydration3 heat cramps, hyper/alemia, patients receiving potassium-sparing diurinto:ication ith A' conduction disturbance.
NU$SIN" CNSI!E$ATINS< >onitor I() ratio and pattern in patients receiving the parIf oliguria occurs, stop infusion promptly and notify physician. ab test< *re$uent serum el
arranted >onitor for and report signs of DI ulceration @esophageal or epigastric pain or
-
7/24/2019 Nursing Drug Cards
32/32
arranted.>onitor for and report signs of DI ulceration @esophageal or epigastric pain orhematemesis.>onitor patients receiving parenteral potassium closely ith cardiac monitoheartbeat is usually the earliest clinical indication of hyper/alemia.Be alert for potassium @hyper/alemia, see S(S, Appendi: *3 may result from any therapeutic dosage, and the paasymptomatic.